申请人:——
公开号:US20030078276A1
公开(公告)日:2003-04-24
Compounds are provided that bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond respectively with Thr245, Thr 247 and Met 253, the first hydrophobic group locates within the S1′ channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compounds specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.
提供了一些与MMP-13的催化结构域发生变构结合的化合物,包括一个疏水基团,第一和第二氢键受体,以及至少一个,最好是两个,第三氢键受体和第二疏水基团。上述特征的质心的笛卡尔坐标在说明书中定义。当配体与MMP-13结合时,第一、第二和第三(存在时)氢键受体分别与Thr245、Thr247和Met253结合,第一个疏水基团位于MMP-13的S1'通道内,第二疏水基团(存在时)相对于溶剂是开放的。这些化合物特异性地抑制基质金属蛋白酶-13酶,因此可用于治疗由组织分解引起的疾病,如心脏病、多发性硬化症、关节炎、动脉粥样硬化和骨质疏松症。